Crit Rev Biochem Mol Biol
Retatrutide carries a dose-related dysesthesia signal at 9-12 mg/week (Phase 3) community doses stay well below this
Don't use this stack if you're pregnant or nursing, under 18, have active cancer, or have contraindications to GLP-1 medications (medullary thyroid carcinoma history, MEN2 syndrome, pancreatitis history)
It was designed in a laboratory to target follicles
Its also been effective in significantly lowering A1C levels in individuals with diabetes
many are marketed under familiar drug names but sold as "research-grade" products meant for laboratory use, not human treatment, and their ingredients, strength, and sterility can vary or be contaminated and mislabeled (goodrx.com)